AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Brief description of study

If you have been diagnosed with non-Hodgkin s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) that relapsed after previous treatment(s), did not respond to previous treatment(s), or for which previous treatment(s) was stopped because the side effects were not tolerable, you may qualify for this Phase I IB study. The main goal of this study is to test the safety of the investigational drug BTCT4465A at different dose levels and schedules to find out what effects, BTCT4465A (given alone or in combination with atezolizumab) has on your cancer.


Clinical Study Identifier: s17-00830
ClinicalTrials.gov Identifier: NCT02500407
Principal Investigator: Catherine M Diefenbach
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.